• Heini Flinck, Anne Rauhio, Bruno Luukinen, Terho Lehtimäki, Anna-Maija Haapala, Tapio Seiskari, and Janne Aittoniemi.
• Department of Clinical Microbiology, Fimlab Laboratories, Tampere, Finland. Electronic address: heini.flinck@fimlab.fi.
• Diagn. Microbiol. Infect. Dis. 2021 Jan 1; 99 (1): 115197.

AbstractAutomated assays for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in coronavirus disease 2019 (COVID-19) diagnostics have recently come available. We compared the performance of the Elecsys® Anti-SARS-CoV-2 and LIAISON® SARS-CoV-2 S1/S2 IgG tests. The seroconversion panel comprised of 120 samples from 13 hospitalized COVID-19 patients. For the sensitivity and specificity testing, samples from COVID-19 outpatients >15 days after positive nucleic acid amplification test (NAAT) result (n = 35) and serum control samples collected before the COVID-19 era (n = 161) were included in the material. Samples for the detection of possible cross-reactions were also tested. Based on our results, the SARS-CoV-2 antibodies can be quite reliably detected 2 weeks after NAAT positivity and 3 weeks after the symptom onset with both tests. However, since some COVID-19 patients were positive only with Elecsys®, the antibodies should be screened against N-antigen (Elecsys®) and reactive samples confirmed with S antigen (LIAISON®), but both results should be reported. In some COVID-19 patients, the serology can remain negative.Copyright © 2020 Elsevier Inc. All rights reserved.

34 keywords...

hide…